What Structure Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 9 | 26 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 26 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sep 21 | Derivative Conversion · C | −12,024 | — | — | 258,228 |
| Coll Crespo Blas | CHIEF MEDICAL OFFICER | Sep 18 | Withheld — tax / exercise cost · F | −10,626 | $11.67 | −$124K | 270,252 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sep 01 | Derivative Conversion · C | −17,817 | — | — | 228,960 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Sep 01 | Exercise / conversion · M | +17,817 | $0.34 | +$6.06K | 246,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 18 | Derivative Conversion · C | −11,817 | — | — | 228,960 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 18 | Exercise / conversion · M | +11,817 | $0.34 | +$4.02K | 240,777 |
| Berrios John Joseph | Chief Commercial Officer | Aug 06 | Grant / award · A | +140,766 | — | — | 140,766 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 04 | Derivative Conversion · C | −11,817 | — | — | 228,960 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Aug 04 | Exercise / conversion · M | +11,817 | $0.34 | +$4.02K | 240,777 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jul 14 | Derivative Conversion · C | −23,634 | — | — | 228,960 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jul 14 | Exercise / conversion · M | +23,634 | $0.34 | +$8.04K | 252,594 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jun 25 | Derivative Conversion · C | −23,634 | — | — | 228,960 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Jun 25 | Exercise / conversion · M | +23,634 | $0.34 | +$8.04K | 252,594 |
| Lang Matthew | COO & GC | Apr 15 | Grant / award · A | +184,614 | — | — | 184,614 |
| Yoon Jun | CHIEF FINANCIAL OFFICER | Mar 19 | Grant / award · A | +104,085 | — | — | 1,401,656 |
| Ma Yingli | CHIEF TECHNOLOGY OFFICER | Mar 19 | Grant / award · A | +32,526 | — | — | 139,917 |
| Hall Ashley | Chief Development Officer | Mar 19 | Grant / award · A | +47,706 | — | — | 155,187 |
| Coll Crespo Blas | CHIEF MEDICAL OFFICER | Mar 19 | Grant / award · A | +75,897 | — | — | 280,878 |
| Stevens Raymond C | CHIEF EXECUTIVE OFFICER | Mar 19 | Grant / award · A | +260,217 | — | — | 1,401,593 |
| Lin Xichen | CHIEF SCIENTIFIC OFFICER | Mar 19 | Grant / award · A | +43,368 | — | — | 228,960 |
Loading...
